My ePortfolio Register   

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.06.17
Views: 1264
Rating:

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA

Dr Hamlin speaks with ecancer at EHA 2017 about a novel dual JAK/SYK inhibitor, cerdulatinib.

He identifies an overall response rate of 50% across all patients in the trial, with responses up to 67% among those with follicular lymphoma, with manageable toxicity profile that responded to dose reduction without loss of efficacy.

Further trials are accruing patients currently.

Dr Hamlin also presented these results at a press conference session, available here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence